Chemomab Therapeutics Ltd. (CMMB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Chemomab Therapeutics Ltd. (CMMB) closed at USD 1.29 on 2026-10-14, a change of -58.8 % over the past year, with a market capitalization of USD 9.45M.

Chemomab Therapeutics Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Chemomab Therapeutics Ltd. key figures

Previous close

USD 1.29 (2026-10-14)

1-year change

-58.8 %

Market cap

USD 9.45M

Enterprise value

USD 2.66M

P/E ratio (trailing)

-1.21

P/E ratio (forward)

-43.00

EPS (trailing)

-1.07

EPS (forward)

-0.03

PEG ratio

n/a

Price to book

1.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.07

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Chemomab Therapeutics Ltd. and compare it with other stocks.